Vadastuximab tedelpar antibody-drug conjugate representing a significant advancement in the approach of acute myeloid leukemia (AML). This groundbreaking therapy precisely targets CD33, a antigen frequently present on leukemic populations. The mechanism involves binding to CD33, resulting in both direct cytotoxicity and enhanced immune-mediated kil

Olaratumab, previously identified as LY3012207 and subsequently recognized as IMC-3G3, represents a unique novel monoclonal antibody therapeutic agent targeting the tumor-associated glycoprotein podoplanin PDPN gp38. This The It antibody exhibits demonstrates shows a particular distinct mechanism of action, primarily mostly largely mediating antibo